Understanding Your Breast Cancer: The IHC ER-PR HER2/NEU Test
When facing a breast cancer diagnosis, uncertainty can feel overwhelming. We understand the anxiety that comes with not knowing which treatment path is right for you. The IHC ER-PR HER2/NEU test provides the clarity you need by identifying the specific characteristics of your cancer cells, helping your medical team create a personalised treatment plan that targets your cancer effectively.
What This Test Reveals About Your Cancer
This advanced immunohistochemistry (IHC) test analyses three critical biomarkers that determine how your breast cancer will respond to different treatments:
- ER (Oestrogen Receptor): Determines if your cancer grows in response to oestrogen
- PR (Progesterone Receptor): Identifies if progesterone fuels your cancer’s growth
- HER2/NEU: Reveals if your cancer has excessive HER2 protein that promotes rapid growth
Understanding these biomarkers helps your oncologist choose treatments that specifically target your cancer’s unique biology, potentially avoiding unnecessary side effects from treatments that wouldn’t work for your specific cancer type.
Who Should Consider This Essential Test?
This test is recommended for anyone with:
- Newly diagnosed breast cancer
- Recurrent breast cancer requiring updated treatment planning
- Metastatic breast cancer where treatment response needs assessment
- Family history of breast cancer requiring comprehensive analysis
- Previous inconclusive biomarker results needing confirmation
If you’re experiencing symptoms like breast lumps, skin changes, or nipple discharge, this test becomes even more critical for determining the right treatment approach from the start.
Why This Test Matters for Your Treatment Journey
Getting this test provides life-changing benefits:
- Personalised Treatment: Identifies which hormonal therapies or targeted drugs will work best for your specific cancer
- Avoid Unnecessary Treatment: Prevents using chemotherapy or other treatments that won’t benefit your cancer type
- Better Outcomes: Targeted treatments based on biomarker results often lead to improved survival rates
- Peace of Mind: Knowing your treatment is specifically designed for your cancer reduces anxiety and builds confidence
- Cost-Effective Care: Avoids spending on ineffective treatments by identifying the right approach from the beginning
Understanding Your Results Clearly
We know waiting for results can be stressful. Our team ensures you receive clear, understandable reports within 3 days:
- Positive ER/PR: Your cancer may respond well to hormonal therapy
- Negative ER/PR: Hormonal treatments may not be effective, guiding toward other options
- HER2 Positive: Targeted therapies like Herceptin may be highly effective
- HER2 Negative: Different treatment approaches will be recommended
Your results will be thoroughly explained by our medical team, and we’ll help you understand what each finding means for your treatment options.
Affordable, Life-Changing Testing
| Test Option | Regular Price | Special Price | Savings |
|---|---|---|---|
| IHC ER-PR HER2/NEU Comprehensive Test | ZAR 1,500 | ZAR 500 |
Note: A doctor’s prescription is required for this test. Prescription requirements do not apply for surgery preparation, pregnancy cases, or international travel documentation.
Why Trust Oracle Genomics?
- Nationwide Coverage: Available throughout South Africa including Johannesburg, Cape Town, Durban, and Pretoria
- Expert Accuracy: Our specialised oncology testing ensures reliable, precise results
- Quick Turnaround: Results delivered within 3 business days
- Professional Team: Experienced medical professionals dedicated to your care
- Advanced Technology: State-of-the-art immunohistochemistry methods
Take Control of Your Cancer Treatment Today
Don’t let uncertainty dictate your treatment journey. Get the clear answers you need to make informed decisions about your health. With locations across South Africa and results in just 3 days, there’s no reason to wait.
Limited Time Offer: Save ZAR 500 on this essential breast cancer biomarker testing. Early detection and accurate biomarker analysis can significantly improve treatment outcomes.
